Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04013854 |
| Title | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Abramson Cancer Center of the University of Pennsylvania |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Duke Cancer Institute | Durham | North Carolina | 27710 | United States | Details | |
| Lancaster General Hospital | Lancaster | Pennsylvania | 17601 | United States | Details | |
| Abramson Cancer Center, University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States | Details |